Artículos por temáticas

Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease

Melancon BJ, Tarr JC, Panarese JD, Wood MR, Lindsley CW.

Drug Discov Today. 2013 Dec;18(23-24):1185-99. doi: 10.1016/j.drudis.2013.09.005. Epub 2013 Sep 17.

Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study

Yasar S, Xia J, Yao W, Furberg CD, Xue QL, Mercado CI, Fitzpatrick AL, Fried LP, Kawas CH, Sink KM, Williamson JD, DeKosky ST, Carlson MC; Ginkgo Evaluation of Memory (GEM) Study Investigators.

Neurology. 2013 Sep 3;81(10):896-903. doi: 10.1212/WNL.0b013e3182a35228. Epub 2013 Aug 2.

The benzazole scaffold: a SWAT to combat Alzheimer's disease

Noël S, Cadet S, Gras E, Hureau C.

Chem Soc Rev. 2013 Oct 7;42(19):7747-62. doi: 10.1039/c3cs60086f. Epub 2013 Jun 24.

Prediction models for assessing long-term outcome in Alzheimer's disease: a review

Wattmo C.

Am J Alzheimers Dis Other Demen. 2013 Aug;28(5):440-9. doi: 10.1177/1533317513488916. Epub 2013 May 20.

Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization

Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, Neal JW, Love S, Nicoll JA, Boche D.

Brain. 2013 Sep;136(Pt 9):2677-96. doi: 10.1093/brain/awt210. Epub 2013 Aug 13.

Alzheimer disease: current concepts & future directions

Musiek ES, Schindler SE.

Mo Med. 2013 Sep-Oct;110(5):395-400.

Walking stabilizes cognitive functioning in Alzheimer's disease (AD) across one year

Winchester J, Dick MB, Gillen D, Reed B, Miller B, Tinklenberg J, Mungas D, Chui H, Galasko D, Hewett L, Cotman CW.

Arch Gerontol Geriatr. 2013 Jan-Feb;56(1):96-103. doi: 10.1016/j.archger.2012.06.016. Epub 2012 Sep 5.

Providing quality palliative care in end-stage Alzheimer disease

Yeaman PA, Ford JL, Kim KY.

Am J Hosp Palliat Care. 2013 Aug;30(5):499-502. doi: 10.1177/1049909112453644. Epub 2012 Jul 18.

Rivastigmine in the treatment of hypersexuality in Alzheimer disease

Canevelli M, Talarico G, Tosto G, Troili F, Lenzi GL, Bruno G.

Alzheimer Dis Assoc Disord. 2013 Jul-Sep;27(3):287-8. doi: 10.1097/WAD.0b013e31825c85ae.

MR imaging features of amyloid-related imaging abnormalities

Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, Tampieri D, Melançon D, Miaux Y, Rippon G, Black R, Lu Y, Brashear HR, Arrighi HM, Morris KA, Grundman M.

AJNR Am J Neuroradiol. 2013 Oct;34(10):1958-65. doi: 10.3174/ajnr.A3500. Epub 2013 Apr 11.

[Memorandum: of the problems of society with uncooperative and peculiar elderly persons. The right of the elderly to autonomy]

Schützendorf E.

Pflege Z. 2013 Apr;66(4):244-7.

[Molecular pathogenesis and development of disease-modifying drugs for Alzheimer's disease]

Takeda M.

Seishin Shinkeigaku Zasshi. 2013;115(1):32-40.

Design of new drugs for the treatment of Alzheimer's disease based on tacrine structure

de Aquino RA, Modolo LV, Alves RB, de Fatima A.

Curr Drug Targets. 2013 Mar;14(3):378-97. doi: 10.2174/138945013804999043.

Interprofessional education in community-based Alzheimer's disease diagnosis and treatment

McCaffrey R, Tappen RM, Lichtstein DM, Friedland M.

J Interprof Care. 2013 Nov;27(6):534-6. doi: 10.3109/13561820.2013.817384. Epub 2013 Jul 23.

NMDA receptor as a newly identified member of the metabotropic glutamate receptor family: clinical implications for neurodegenerative diseases

Chung C.

Mol Cells. 2013 Aug;36(2):99-104. doi: 10.1007/s10059-013-0113-y. Epub 2013 Jun 4.